SecProbe.io

CORRESP
1
filename1.htm

    March 30, 2017

    United States Securities and Exchange Commission

    100 F Street, NE

    Washington, DC 20549

    Attention:
     Mr. Jim B. Rosenberg

    Ms. Sasha Parikh

Re:
Regen BioPharma, Inc.

Form
10-K for the Fiscal Year Ended September 30, 2016

Filed
December 21, 2016

File
No. 333-191725

Dear
Mr. Rosenberg and Ms. Parikh

With
regard to the comments of the Staff (the “Staff”) as set forth in its letter dated March 09, 2017 (the “Comment
Letter”) relating to the abovementioned Exchange Act filing made by Regen Biophama, Inc. (The "Company").

Comment
1.

For
the years ended September 30, 2015 and 2016 the Company recognized an expense related to the issuance of securities for less than
fair value on the following three types of transactions:

 (a) Conversions
                                         of convertible securities convertible in accordance with the terms of the instrument

 (b) Issuances
                                         of equity securities for cash at less than fair value

 (c) Settlement
                                         of existing non convertible debt through the issuance of equity securities for less than
                                         fair value

In
reviewing the aforementioned transactions, the Company has determined that an expense for issuance of securities for less than
fair value should not have been recognized with regards to conversions of convertible securities convertible in accordance with
the terms of the instrument and Issuances of equity securities for cash at less than fair value. Expense for issuance of securities
for less than fair value remains recognized with regards to settlement of existing non convertible debt through the issuance of
equity securities for less than fair value in accordance with ASC 470 40.

Concurrently
with this response, the Company is filing amended periodic filings for the following periods.

Quarter
ended March 31, 2015

Quarter
ended June 30, 2015

Year
ended September 30, 2015

Quarter
ended December 31, 2015

Quarter
ended March 31, 2016

Quarter
ended June 30, 2016

Year
ended September 30, 2016

Quarter
ended December 31, 2016

Comments
2 and 3

The
relevant sections for the 10-K for the year ended September 30, 2015 and 2016 have been amended to read as follows:

10-K
2015

Item
9A. Controls and Procedures

 a)
Evaluation of disclosure controls and procedures.

The
principal executive officer and principal financial officer have evaluated the Company’s disclosure controls and procedures
as of September 30, 2015. Based on this evaluation, they have concluded that the disclosure controls and procedures were effective
to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities
Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission’s
rules and forms and to ensure that information required to be disclosed by the Company in the reports that it files or submits
under the Securities Exchange Act of 1934 is accumulated and communicated to the Company’s management, including its principal
executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions
regarding required disclosure. David Koos is the Company’s CEO and Todd Caven is the Company’s CFO. They function
as the Company’s principal executive officer and principal financial officer respectively.

b)
Management’s annual report on internal control over financial reporting.

Management
of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in
Rule 13a-15(f) promulgated under the Securities and Exchange Act of 1934. Rule 13a-15(f) defines internal control over financial
reporting as follows:

“The
term internal control over financial reporting is defined as a process designed by, or under the supervision of, the issuer's
principal executive and principal financial officers, or persons performing similar functions, and effected by the issuer's board
of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles
and includes those policies and procedures that:

Pertain
to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the
assets of the issuer;

Provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with
authorizations of management and directors of the issuer; and

Provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer's
assets that could have a material effect on the financial statements.”

The
Company’s internal control over financial reporting is a process designed under the supervision of the Company’s management
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial
statements for external purposes in accordance with U.S. generally accepted accounting principles.

In
designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures,
no matter how well conceived and operated, can provide only a reasonable, not absolute, assurance that the objectives of the disclosure
controls and procedures are met.

The
Company’s management assessed the effectiveness of its internal control over financial reporting as of September 30, 2015
based on the framework in Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework. Based on its assessment,
management believes that, as of September 30, 2015, the Company’s internal control over financial reporting is effective.

Management's
report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities
and Exchange Commission that permit the company to provide only management's report in this annual report. This exemption for
smaller reporting companies provided under the temporary rules referenced above has been made permanent under Section 989G of
the Dodd-Frank Wall Street Reform and Consumer Protection Act.

(c)
There have been no changes during the quarter ended September 30, 2015 in the Company’s internal controls over financial
reporting that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

10-K
2016

a)
Evaluation of disclosure controls and procedures.

The
principal executive officer and principal financial officer have evaluated the Company’s disclosure controls and procedures
as of September 30, 2016. Based on this evaluation, they have concluded that the disclosure controls and procedures were effective
to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities
Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission’s
rules and forms and to ensure that information required to be disclosed by the Company in the reports that it files or submits
under the Securities Exchange Act of 1934 is accumulated and communicated to the Company’s management, including its principal
executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions
regarding required disclosure. David Koos is the Company’s CEO and Todd Caven is the Company’s CFO. They function
as the Company’s principal executive officer and principal financial officer respectively.

b)
Management’s annual report on internal control over financial reporting.

Management
of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in
Rule 13a-15(f) promulgated under the Securities and Exchange Act of 1934. Rule 13a-15(f) defines internal control over financial
reporting as follows:

“The
term internal control over financial reporting is defined as a process designed by, or under the supervision of, the issuer's
principal executive and principal financial officers, or persons performing similar functions, and effected by the issuer's board
of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles
and includes those policies and procedures that:

Pertain
to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the
assets of the issuer;

Provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with
authorizations of management and directors of the issuer; and

Provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer's
assets that could have a material effect on the financial statements.”

The
Company’s internal control over financial reporting is a process designed under the supervision of the Company’s management
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial
statements for external purposes in accordance with U.S. generally accepted accounting principles.

In
designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures,
no matter how well conceived and operated, can provide only a reasonable, not absolute, assurance that the objectives of the disclosure
controls and procedures are met.

The
Company’s management assessed the effectiveness of its internal control over financial reporting as of September 30, 2016
based on the framework in Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework. Based on its assessment,
management believes that, as of September 30, 2016, the Company’s internal control over financial reporting is effective.

Management's
report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities
and Exchange Commission that permit the company to provide only management's report in this annual report. This exemption for
smaller reporting companies provided under the temporary rules referenced above has been made permanent under Section 989G of
the Dodd-Frank Wall Street Reform and Consumer Protection Act.

(c)
There have been no changes during the quarter ended September 30, 2016 in the Company’s internal controls over financial
reporting that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Thank
you for your kind assistance and the courtesies that you have extended to assist us in fulfilling our obligations under the Securities
and Exchange Act of 1934. If, at any time, you have any further questions, please let us know.

Sincerely,

David
R. Koos,

Chairman
& CEO